SuperworthKalaris Therapeutics shares outstanding KLRS
Diluted shares outstanding, averaged over each quarter, from 2019.
- Latest quarter, to Jun 30, 2026
- 23.8M
- On a year earlier
- +27.2%
- more shares
Kalaris Therapeutics had 23.8M diluted shares outstanding on average in Q2 FY26, the quarter to Jun 30, 2026.
That is 27.2% more than a year earlier, so each share owns a little less of the company.
Shares outstanding over time
Fiscal year by fiscal year
| Fiscal year | Shares, fourth quarter | Change |
|---|---|---|
| FY2024 | 5M | +1% |
| FY2023 | 5M | +23% |
| FY2022 | 4M | +46% |
| FY2021 | 2.8M | +3% |
| FY2020 | 2.7M | +3285% |
| FY2019 | 79.3K | n/a |
Each fiscal year is the twelve months to its fourth quarter, shown as the fourth quarter's average share count.
Quarter by quarter
| Quarter | Ended | Shares outstanding | On a year earlier |
|---|---|---|---|
| Q2 FY26 | 23.8M | +27% | |
| Q1 FY26 | 23.7M | +485% | |
| Q3 FY25 | 18.7M | +1283% | |
| Q2 FY25 | 18.7M | +1311% | |
| Q1 FY25 | 4.1M | +209% | |
| Q4 FY24 | 5M | +1% | |
| Q3 FY24 | 1.4M | −73% | |
| Q2 FY24 | 1.3M | −68% | |
| Q1 FY24 | 1.3M | −68% | |
| Q4 FY23 | 5M | +23% | |
| Q3 FY23 | 5M | +34% | |
| Q2 FY23 | 4.1M | +47% |
What the shares outstanding tells you
Diluted shares outstanding, averaged over the period. Fewer shares means each one owns more of the company.
A falling count usually means buybacks. A rising one means stock pay, acquisitions paid in shares or new shares sold.
More on Kalaris Therapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.